from the rapidly evolving subject of oncology study, exact and economical mutation screening is essential for building qualified therapies. The KRAS solutions System plays a pivotal role Within this landscape by providing detailed solutions for KRAS mutation profiling and Evaluation. KRAS mutations, found in about 95% of RAS-connected oncogenic alt